Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptimmune reports strong Q1 results, eyes market leadership with afami-cel

Adaptimmune Therapeutics shows strong performance and progress in Q1 2024.
Strengths lie in innovative therapies, financial stability, and clear development plans.
Challenges include managing debt impact, FDA processes, and successful product launches.
Opportunities exist in market leadership, upcoming presentations, and growth strategies.

Adaptimmune achieves commercial milestone with Tecelra launch, poised for growth

Adaptimmune's Q2 performance reflects a transformative phase as it transitions into a commercial-stage company with a strong financial position and a focus on innovative cell therapies.
While facing challenges in operational execution and revenue forecasting, the company's strategic strengths lie in its pioneering treatments, robust pipeline, and customer-centric approach.
By capitalizing on opportunities for market expansion, strategic partnerships, and operational optimization, Adaptimmune is poised to drive growth and establish itself as a key player in the cell therapy sector.

Adaptimmune targets breakeven by 2027 with strong sarcoma franchise

Adaptimmune Therapeutics is strategically positioned to achieve operating breakeven by 2027 through significant cost reductions and a focus on their sarcoma franchise with Tecelra and lete-cel.
The company's financial stability, positive trial results, and revenue targets indicate a strong growth trajectory and confidence in their business strategy.
While facing challenges in cost reduction and workforce restructuring, Adaptimmune Therapeutics has opportunities to capitalize on market expansion and product efficacy to drive future growth.
Overall, the company's performance in Q3 reflects a proactive approach to financial sustainability and market competitiveness in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that two of its executive leadership team members based in the UK will leave the Company next year.

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development Conference Call Participants Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Paul Jeng - Guggenheim Yen-Der Li - Leerink Partners Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright George Farmer - Scotiabank Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello and welcome to the Adaptimmune Therapeutics Third Quarter 2024 Results Conference Call.

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025 Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16 Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patients Planned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million in aggregate cost savings over the next four years enables company to target an operating breakeven during 2027 At the end of Q3, Adaptimmune had Total Liquidity1 of $186.1 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the third quarter ended September 30, 2024. The Company will host a live webcast at 4:30 p.m.

Adaptimmune Reports Q3 2024 Financial and Business Updates

42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025 Company to host virtual KOL event Monday, November 18, 2024; 2:30 PM EST featuring Dr. Sandra D'Angelo, M.D. (Memorial Sloan Kettering Cancer Center) - register here Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced data from the primary analysis of its pivotal Phase 2 IGNYTE-ESO trial of lete-cel in people with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) who received previous anthracycline-based therapy.

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and medical conferences in November and December. Society for Immunotherapy of Cancer (SITC) 39 th annual meeting, November 6-10, Houston, TX Podium presentation: "Delivering on the Promise of Cell Therapies for Solid Tumors: T-cell Therapy for Synovial Sarcoma" / Jo Brewer, PhD, Chief Scientific Officer, Adaptimmune.

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the third quarter ended September 30, 2024, after the US markets close on Wednesday, November 13, 2024. Following the announcement, the Company will host a live webcast at 4:30 p.m.

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in two investment bank conferences this September. Wells Fargo Healthcare Conference, Boston, MA Fireside chat: Wednesday September 4, 2024, at 4:30 PM EDT.

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Dan Od-Cohen - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Joanna Brewer - Chief Scientific Officer Dennis Williams - Senior Vice President, Late Stage Development John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Matthew Cowper - Leerink Partners Paul Jeng - Guggenheim Securities Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities George Farmer - Scotiabank Arthur He - H.C. Wainwright Kuan-Hung Lin - Wells Fargo Michael Kim - Zacks Small-Cap Research Alexandre Bouilloux - Barclays Operator Good day and welcome to the Adaptimmune Second Quarter 2024 Conference Call.

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumor Patients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive orders At the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m.

Adaptimmune Reports Q2 2024 Financial and Business Updates

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the second quarter ended June 30, 2024, before the US markets open on Monday, August 12, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind gene therapy to treat adult patients with a rare type of cancer that affects soft tissues who have received prior chemotherapy.

US FDA approves Adaptimmune's gene therapy for rare type of cancer

PHILADELPHIA & OXFORD, England--(BUSINESS WIRE)--Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses.

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Guardant Health Inc

Viking Therapeutics

For most of the year, biotech has been one of the most explosive sectors on the market. Far from over, further upside is likely, thanks to some of the top biotech stocks with catalysts.

3 Biotech Moonshots With Imminent Catalyst Potential

Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further.

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

We are initiating coverage of Adaptimmune Therapeutics plc ADAP with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price. Adaptimmune designs, develops, manufactures, and delivers innovative cell therapies via the company's unique T-cell receptor (TCR) platform to treat cancers across multiple solid tumor types.

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient population Full results from the pivotal IGNYTE-ESO trial are expected in late 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 3, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, is presenting data from its pivotal IGNYTE-ESO trial of lete-cel (letetresgene autoleucel), an engineered cell therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS) at the American Society of Clinical Oncology's (ASCO) annual meeting. Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center will present "Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial" in an oral session at 11:30 a.m.

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Galapagos

Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications Adaptimmune will hold a conference call tomorrow (May 31 st ) at 8 a.m. EDT (webcast link here and more details below) Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 30, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), and Galapagos NV (NA: GLPG) (NASDAQ: GLPG) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer Dennis Williams - Head of Late Stage Development Cintia Piccina - Chief Commercial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright Peter Lawson - Barclays Operator Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call.

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to be presented at ASCO Cash runway into late 2025 Conference call today at 8 a.m. EDT webcast link HERE Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the first quarter ended March 31, 2024.

Adaptimmune Reports Q1 2024 Financial and Business Updates

Hercules Capital

First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company's balance sheet as it executes on its sarcoma franchise with the commercial launch of afami-cel later this year and lete-cel planned for 2026.

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended March 31, 2024, before the US markets open on Wednesday, May 15, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon.

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

News for Adaptimmune Therapeutics Stock (ADAP)